Cantargia AB - ESG Rating & Company Profile powered by AI
This Disclosure score covers seventeen United Nations SDGs including: 'Gender Equality', 'Climate Action' and 'Peace, Justice & Strong Institutions'. Browse to the end of this webpage for potential risks for Cantargia AB based on industry, geography and marketcap. This report of Cantargia AB is assembled by All Street Sevva using proprietary Cognitive Robots.
Cantargia AB in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 5.8; made up of an environmental score of 5.3, social score of 8.0 and governance score of 4.0.
5.8
Medium ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Caladrius Biosciences Inc | 8.0 | High |
| 1 | Can Fite Biopharma Ltd | 8.0 | High |
| 521 | Smruthi Organics Ltd | 5.9 | High |
| 521 | Vectura Group PLC | 5.9 | High |
| 541 | Cantargia AB | 5.8 | High |
| 541 | Amplia Therapeutics Ltd | 5.8 | High |
| 541 | Avenue Therapeutics Inc | 5.8 | High |
| ... | ... | ... | |
| 1970 | Zyden Gentec Ltd | 0.0 | Low |
| 1970 | iNtRON Biotechnology Inc | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does Cantargia AB have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes Cantargia AB disclose current and historical energy intensity?
Sign up for free to unlockDoes Cantargia AB report the average age of the workforce?
Sign up for free to unlockDoes Cantargia AB reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes Cantargia AB disclose its ethnicity pay gap?
Sign up for free to unlockDoes Cantargia AB disclose cybersecurity risks?
Sign up for free to unlockDoes Cantargia AB offer flexible work?
Sign up for free to unlockDoes Cantargia AB have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes Cantargia AB disclose the number of employees in R&D functions?
Sign up for free to unlockDoes Cantargia AB conduct supply chain audits?
Sign up for free to unlockDoes Cantargia AB disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes Cantargia AB conduct 360 degree staff reviews?
Sign up for free to unlockDoes Cantargia AB disclose the individual responsible for D&I?
Sign up for free to unlockDoes Cantargia AB disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes Cantargia AB disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes Cantargia AB disclose water use targets?
Sign up for free to unlockDoes Cantargia AB have careers partnerships with academic institutions?
Sign up for free to unlockDid Cantargia AB have a product recall in the last two years?
Sign up for free to unlockDoes Cantargia AB disclose incidents of discrimination?
Sign up for free to unlockDoes Cantargia AB allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas Cantargia AB issued a profit warning in the past 24 months?
Sign up for free to unlockDoes Cantargia AB disclose parental leave metrics?
Sign up for free to unlockDoes Cantargia AB disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes Cantargia AB disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes Cantargia AB disclose the pay ratio of women to men?
Sign up for free to unlockDoes Cantargia AB support suppliers with sustainability related research and development?
Sign up for free to unlockDoes Cantargia AB disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes Cantargia AB reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs Cantargia AB involved in embryonic stem cell research?
Sign up for free to unlockDoes Cantargia AB disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes Cantargia AB disclose its waste policy?
Sign up for free to unlockDoes Cantargia AB report according to TCFD requirements?
Sign up for free to unlockDoes Cantargia AB disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes Cantargia AB disclose energy use targets?
Sign up for free to unlockDoes Cantargia AB disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes Cantargia AB have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for Cantargia AB
These potential risks are based on the size, segment and geographies of the company.
Cantargia AB (publ), a biotechnology company, engages in the research and development of antibody-based treatments for life threatening diseases. The company is developing CAN04, an antibody against Interleukin-1 Receptor Accessory Protein (IL1RAP) to recognize cancer cells and stimulate natural immune system to destroy such cells, as well as block the tumor inflammation that is driven by the Interleukin-1 system and is under phase IIa clinical trial; and CAN10, an antibody against IL1RAP for treatment of autoimmune and inflammatory diseases, including systemic sclerosis and myocarditis, and is under preclinical trial. It is also developing CANxx antibodies against IL1RAP. The company has collaboration agreements with Patheon Biologics BV and BioWa Inc. for the manufacture and production of CAN04; and Specialized Medical Services-oncology BV for the clinical study of CAN04. Cantargia AB (publ) was founded in 2010 and is based in Lund, Sweden.